15. Influence of the number of administered doses: all three versus less than three doses.

Outcomes	Age Group (years)	Studies	RR if 3 doses (95% CI)	RR if 1‐2 doses (95% CI)
CIN2+ due to HPV16/18	15‐26	5 (FUTURE II trial (ph3,4v); Japanese trial (ph2,2v); PATRICIA trial (ph3,2v); Phase2 trial (ph2,1v); Chinese trial (ph3,2v)_young)	0.07 (0.03 to 0.14)*	0.10 (0.04 to 0.26)*
	24‐45	2 (FUTURE III trial (ph3,4v); VIVIANE trial (ph3,2v))	0.14 (0.03 to 0.79)*	0.98 (0.20 to 4.83)
CIN3+ due to HPV16/18	15‐26	1 (PATRICIA trial (ph3,2v))	0.20 (0.04 to 0.91)*	0.04 (0.01 to 0.74)*
Incident HPV16/18 infection	15‐26	3 (Japanese trial (ph2,2v); Phase2 trial (ph2,1v);Chinese trial (ph3,2v)_young)	0.20 (0.10 to 0.41)*	0.47 (0.26 to 0.84)*
6‐month persistent HPV16/18 infection	15‐26	2 (Japanese trial (ph2,2v);Chinese trial (ph3,2v)_young)	0.05 (0.01 to 0.27)*	0.12 (0.03 to 0.42)*
	24‐45	2 (FUTURE III trial (ph3,4v);VIVIANE trial (ph3,2v))	0.15 (0.09 to 0.27)*	0.34 (0.19 to 0.61)*
12‐month persistent HPV16/18 infection	15‐26	3 (Japanese trial (ph2,2v);CVT (ph3,2v); Chinese trial (ph3,2v)_young)	0.09 (0.05 to 0.19)*	0.13 (0.06 to 0.33)*

*Vaccine efficacy in women being HPV16/18 DNA negative at enrolment and having received all three or less than three doses (computed from trials where per‐protocol [all doses administered] and intention‐to‐treat analyses [at least one dose administered] are reported).